🚨How some peptide labs actually work.
- 99.9% purity is a $10 add-on.
- The fentanyl screen comes back “not detected” by default.
- Express service gets you results before the sample even arrives, and for $9 a brand, the same COA goes on 11 other websites.
Ask your vendor who tested it, and whether the lab ever saw the vial.
Labs we recommend : @TrustPointe , @finnrick_tests , Janoshik.
@Dustin_Newman sums it up nicely. We’ve been saying it for over a year. Sounds like people are finally listening.
I’ll add that many “rapid” tests are validated on each formulation - the specific recipe of peptide and fillers in the product.
Labs in the black market peptide space are blind to the formulations, so they (and you) are taking a big risk when they use these methods.
Apologies for the novel, but this is one that irritates me. A negative PCR ≠ a USP 71(or 73) passing sterility.
There's a significant difference between detecting microbial DNA and demonstrating the absence of viable microbial contamination using a validated sterility procedure.
USP <71> testing relies on microbial growth in 2 types of media over 14 days. PCR detects nucleic acid sequences. Depending on the assay, that DNA may originate from viable organisms, dead organisms, or residual microbial material. A negative PCR result also does not establish that viable contamination is absent, particularly when the organism concentration is below the PCR detection limit.
It's more than a theoretical concern, or semantics. Broad-range 16S PCR for sterility screening reported detection sensitivities ranging from 10 to 100 CFU/mL. Thats substantial when evaluating products where contamination may consist of only a few viable organisms.
Another important distinction is that 16S PCR primarily detects bacteria. It does not adequately address fungal contamination. Adding a fungal PCR assay improves coverage, but it does not automatically establish equivalence to USP <71>. Much of the failed USP 71 sterility tests of RUO
I also reviewed and frequently used commercial PCR systems. Sartorius, one of the major manufacturers in this field, has published studies demonstrating favorable comparisons between its Microsart PCR assays and traditional compendial methods.
However, Sartorius explicitly states in its own technical documentation that its Microsart ATMP system is not a replacement for classical USP <71> sterility testing.
It's good for a screen for products manufactured in highly controlled and regulated cGMP environments. I often used it to quickly screen raw materials and finished productstopical formulations. I would never rely on it for products where nothing concerning the manufacturing can be confirmed, or where the product would be injected.
There is a difference between demonstrating comparable analytical performance in a limited study and validating a method as a replacement for compendial sterility testing across different pharmaceutical formulations.
A 2019 study published in the Journal of Clinical Microbiology evaluated 118 microbial isolates using traditional USP <71> and alternative automated culture systems. One alternative system detected only 71.2% of the organisms after extended incubation.
Validated USP 71 methods do exist.
At @Vanguard_Lab , we offer traditional USP <71> sterility testing as well as rapid sterility testing using the Charles River Celsis ATP bioluminescence system, validated as an alternative to USP <71>. To put in perspective, we paid over 100K for the instrument and nearly another 100k on validation and method suitability studies of more than 50 different peptides at different mgs, different filler materials, and different combinations of peptides.
Celsis uses microbial growth followed by ATP-based detection, allowing a shortened incubation period while retaining a growth-based approach to detecting viable contamination.
We also participate in independent, third-party Pharma ISO accredited proficiency testing with our traditional USP <71> and USP <71>-equivalent rapid sterility methods That provides an additional external assessment of laboratory performance beyond our internal quality controls and method validation.
USP also specifically addresses certain rapid sterility technologies under chapters <72> and <73>, including respiration-based detection and ATP bioluminescence for applicable short-life products.
PCR is not inherently excluded from alternative-method validation. USP <1223> provides a framework for evaluating alternative microbiological technologies. However, I have not found evidence that a commercially available standalone PCR kit is universally recognized by USP as a direct replacement for USP <71>, Nor have I seen any evidence that anyone in this space using PCR is doing method suitability on PC methods or participating in proficiency testing.
If a laboratory is advertising PCR screen as a USP <71> sterility test, I would ask to see the validation demonstrating that equivalence, including low-level microbial recovery, bacterial and fungal coverage, product-specific suitability, assay inhibition, and detection probability at very low contamination levels.
I would also want to know whether that laboratory participates in independent proficiency testing for the methodology being offered.
We use molecular methods at Vanguard, and consider PCR an extremely valuable tool for pathogen detection and identification. We use it daily in our food and pharma departments. It can also be useful for rapid preliminary screening but screening and compendial sterility testing are not interchangeable.
There is nothing wrong with offering PCR microbial screening. There is a problem with advertising that screening as USP <71> sterility testing without the necessary supporting validation. If someone wants us to provide a rapid PCR or other rapid micro method we are happy to do so, but we will not list it on our COA as USP 71, or sterility.
The distinction matters scientifically, analytically, and from a regulatory standpoint.
Apologies for the novel, but this is one that irritates me. A negative PCR ≠ a USP 71(or 73) passing sterility.
There's a significant difference between detecting microbial DNA and demonstrating the absence of viable microbial contamination using a validated sterility procedure.
USP <71> testing relies on microbial growth in 2 types of media over 14 days. PCR detects nucleic acid sequences. Depending on the assay, that DNA may originate from viable organisms, dead organisms, or residual microbial material. A negative PCR result also does not establish that viable contamination is absent, particularly when the organism concentration is below the PCR detection limit.
It's more than a theoretical concern, or semantics. Broad-range 16S PCR for sterility screening reported detection sensitivities ranging from 10 to 100 CFU/mL. Thats substantial when evaluating products where contamination may consist of only a few viable organisms.
Another important distinction is that 16S PCR primarily detects bacteria. It does not adequately address fungal contamination. Adding a fungal PCR assay improves coverage, but it does not automatically establish equivalence to USP <71>. Much of the failed USP 71 sterility tests of RUO
I also reviewed and frequently used commercial PCR systems. Sartorius, one of the major manufacturers in this field, has published studies demonstrating favorable comparisons between its Microsart PCR assays and traditional compendial methods.
However, Sartorius explicitly states in its own technical documentation that its Microsart ATMP system is not a replacement for classical USP <71> sterility testing.
It's good for a screen for products manufactured in highly controlled and regulated cGMP environments. I often used it to quickly screen raw materials and finished productstopical formulations. I would never rely on it for products where nothing concerning the manufacturing can be confirmed, or where the product would be injected.
There is a difference between demonstrating comparable analytical performance in a limited study and validating a method as a replacement for compendial sterility testing across different pharmaceutical formulations.
A 2019 study published in the Journal of Clinical Microbiology evaluated 118 microbial isolates using traditional USP <71> and alternative automated culture systems. One alternative system detected only 71.2% of the organisms after extended incubation.
Validated USP 71 methods do exist.
At @Vanguard_Lab , we offer traditional USP <71> sterility testing as well as rapid sterility testing using the Charles River Celsis ATP bioluminescence system, validated as an alternative to USP <71>. To put in perspective, we paid over 100K for the instrument and nearly another 100k on validation and method suitability studies of more than 50 different peptides at different mgs, different filler materials, and different combinations of peptides.
Celsis uses microbial growth followed by ATP-based detection, allowing a shortened incubation period while retaining a growth-based approach to detecting viable contamination.
We also participate in independent, third-party Pharma ISO accredited proficiency testing with our traditional USP <71> and USP <71>-equivalent rapid sterility methods That provides an additional external assessment of laboratory performance beyond our internal quality controls and method validation.
USP also specifically addresses certain rapid sterility technologies under chapters <72> and <73>, including respiration-based detection and ATP bioluminescence for applicable short-life products.
PCR is not inherently excluded from alternative-method validation. USP <1223> provides a framework for evaluating alternative microbiological technologies. However, I have not found evidence that a commercially available standalone PCR kit is universally recognized by USP as a direct replacement for USP <71>, Nor have I seen any evidence that anyone in this space using PCR is doing method suitability on PC methods or participating in proficiency testing.
If a laboratory is advertising PCR screen as a USP <71> sterility test, I would ask to see the validation demonstrating that equivalence, including low-level microbial recovery, bacterial and fungal coverage, product-specific suitability, assay inhibition, and detection probability at very low contamination levels.
I would also want to know whether that laboratory participates in independent proficiency testing for the methodology being offered.
We use molecular methods at Vanguard, and consider PCR an extremely valuable tool for pathogen detection and identification. We use it daily in our food and pharma departments. It can also be useful for rapid preliminary screening but screening and compendial sterility testing are not interchangeable.
There is nothing wrong with offering PCR microbial screening. There is a problem with advertising that screening as USP <71> sterility testing without the necessary supporting validation. If someone wants us to provide a rapid PCR or other rapid micro method we are happy to do so, but we will not list it on our COA as USP 71, or sterility.
The distinction matters scientifically, analytically, and from a regulatory standpoint.
This is the Linearity test
In order to know the label claim / mg calculations are accurate, you have to know the response by concentration is linear across the range of concentration you test. There are things that can cause it to be nonlinear.
For example: flooding the detector. There is only so much UV light to be absorbed; the response can only go so high.
If you put a high enough concentration through, and the response tops out at 140%, you could report a result of 140% (where you maxed out) when the real value is much higher.
Identification by Retention Time
Putting in the work to validate we can see the difference in compounds (little teal/aqua is eloralintide)
It’s so pretty 🤩 😍
We’ve had two cases this week where the molecular weight (mass spec) was the same as the reference standard, but they failed HPLC-UV Identification by Retention Time
Multiple ID tests are important because they all have a weakness:
Retention Time: poor method resolution
UV Spetra: lot of peptides look similar, have similar maxima and minima
Mass Spec: molecules have the same weight but the amino acids are in the wrong order
Makes sense; USP never relies on one ID test.